While our analysis identified a BRCA2 (p.E51K) mutation present alongside NF2 gene loss in the same cancer clone across all tumor samples, it is important to acknowledge that the evidence supporting BRCA2 (p.E51K) as a driver mutation in meningioma is not well-established. This evidence concerns the gene NF2 and neoplasm.